GlobeImmune, Inc. has withdrawn its IPO in the amount of $65 million.

GlobeImmune Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. It has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The Company's oncology product candidates include GI-6301, GI-6207 and GI-4000. The Company's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.